熱門資訊> 正文
AN 2 Therapeutics任命生物技术资深人士Cameron Trenor为CMO
2026-08-24 19:44
- AN2 Therapeutics (ANTX) appointed Cameron Trenor, M.D., as chief medical officer, bringing more than two decades of clinical and drug development experience.
- Trenor most recently served as chief medical officer at Cellarity, where he established the company's medical organization and led its lead program through its first IND submission and the start of a global first-in-human study.
- AN2 Therapeutics (ANTX) said Trenor will help advance its pipeline, which includes hematologic and infectious-disease programs, oncology candidates, and research programs targeting oncology, bone disorders, and infectious diseases.
More on AN2 Therapeutics
- AN2 rises after early-stage trial data for Chagas disease therapy
- Seeking Alpha’s Quant Rating on AN2 Therapeutics
- Historical earnings data for AN2 Therapeutics
- Financial information for AN2 Therapeutics
推薦文章
今夜加息概率升破92%！全球風暴即將來襲？覆盤近三輪加息周期，這次會走2015還是2022年劇本？
5%美債收益率風暴來襲！再融資炸彈倒計時開啟，誰會是第一個犧牲品？
美參議院加密市場結構法案程序性投票未獲通過 兩黨談判破裂致立法進程受阻
利率決議前夕黃金「搶跑」！美聯儲兩難困境正被看穿：加息是利空出盡，不加息金價衝5000？
扎克伯格稱更青睞依靠評估人員確保AI安全 而非放緩發展
華盛早報 | 香港首份五年規劃+26年施政報告今日公佈！加密貨幣《清晰法案》遭否；OpenAI再融資：估值已達1.2萬億美元
攜程2026Q2淨利潤同比下降，受處罰費用影響，錄得淨虧損24億元！
加密貨幣法案折戟美國參議院！比特幣、以太幣跌至6月來最低
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
